Enoxacin-d8 is intended for use as an internal standard for the quantification of enoxacin by GC- or LC-MS. Enoxacin is a fluoroquinolone antibiotic.1,2,3,4 It is active against clinical isolates of a variety of Gram-positive and Gram-negative bacteria, including S. aureus, E. coli, K. pneumoniae, P. aeruginosa, and S. marcescens (MIC50s = 1, 0.12, 0.25, 0.5, and 1 mg/L, respectively).1 Enoxacin inhibits S. aureus DNA gyrase supercoiling activity and topoisomerase IV DNA decatenation (IC50s = 126 and 26.5 µg/ml, respectively).2 It increases survival in mouse models of systemic S. aureus, E. coli, K. pneumoniae, P. aeruginosa, and S. marcescens infection with ED50 values of 15.1, 2.2, 4.1, 120.3, and 7.6 mg/kg, respectively.3 Enoxacin (4 and 8 mg/kg per day) also reduces tumor growth in a 143B human osteosarcoma mouse xenograft model.4 Formulations containing enoxacin have previously been used in the treatment of urinary tract infections and gonorrhea.
1.Clarke, A.M., Zemcov, S.J., and Campbell, M.E.In-vitro activity of pefloxacin compared to enoxacin, norfloxacin, gentamicin and new β-lactamsJ. Antimicrob. Chemother.15(1)39-44(1985) 2.Takei, M., Fukuda, H., Kishii, R., et al.Target preference of 15 quinolones against Staphylococcus aureus, based on antibacterial activities and target inhibitionAntimicrob. Agents Chemother.45(12)3544-3547(2001) 3.Ozaki, M., Matsuda, M., Tomii, Y., et al.In vivo evaluation of NM441, a new thiazeto-quinoline derivativeAntimicrob. Agents Chemother.35(12)2496-2499(1991) 4.Luo, X., Liu, X., Tao, Q., et al.Enoxacin inhibits proliferation and invasion of human osteosarcoma cells and reduces bone tumour volume in a murine xenograft modelOncol. Lett.20(2)1400-1408(2020)